Endocrine side effects of immune checkpoint inhibitors

被引：20

作者：

Cardona, Zulma ^{[1
]}

Sosman, Jeffrey A. ^{[2
]}

Chandra, Sunandana ^{[2
]}

Huang, Wenyu ^{[1
]}

机构：

[1] Northwestern Univ, Div Endocrinol Metab & Mol Med, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Northwestern Univ, Div Hematol & Oncol, Feinberg Sch Med, Chicago, IL USA

来源：

FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷

关键词：

immune checkpoint inhibitor (ICI); endocrine side effects; hypophysitis; thyroiditis; type1; diabetes; adrenalitis; adrenal insufficiency; central diabetes insipidus; IPILIMUMAB-INDUCED HYPOPHYSITIS; CELL LUNG-CANCER; QUALITY-OF-LIFE; ADVERSE EVENTS; RETROSPECTIVE ANALYSIS; ADRENAL INSUFFICIENCY; THYROID ANTIBODIES; PD-1; EXPRESSION; NIVOLUMAB; MANAGEMENT;

D O I：

10.3389/fendo.2023.1157805

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we describe our current understanding of the autoimmune endocrinopathies as a result of the use of ICIs. We will review the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of the most commonly encountered endocrinopathies, including thyroiditis, hypophysitis, Type 1 diabetes, adrenalitis, and central diabetes insipidus.

引用

页数：12

共 50 条

[41] A Novel Etiology of Hypophysitis Immune Checkpoint Inhibitors
Fernandes, Stuti
Varlamov, Elena V.
McCartney, Shirley
Fleseriu, Maria
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2020, 49 (03) : 387 - +
[42] Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
Paschou, Stavroula A.
Liontos, Michael
Eleftherakis-Papaiakovou, Evangelos
Stefanaki, Katerina
Markellos, Christos
Koutsoukos, Konstantinos
Zagouri, Flora
Psaltopoulou, Theodora
Dimopoulos, Meletios-Athanasios
FRONTIERS IN ONCOLOGY, 2022, 12
[43] Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice
Parthymos, Ioannis
Liamis, George
Dounousi, Evangelia
Pentheroudakis, George
Mauri, Davide
Zarkavelis, George
Florentin, Matilda
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 151
[44] Common endocrine system adverse events associated with immune checkpoint inhibitors☆
Li, Ying
Zhao, Junfeng
Wang, Yue
Xu, Yali
Li, Ruyue
Zhao, Ying
Dong, Xue
Yao, Xiujing
Li, Yintao
CANCER PATHOGENESIS AND THERAPY, 2024, 2 (03): : 164 - 172
[45] Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians
Deligiorgi, Maria V.
Panayiotidis, Mihalis I.
Trafalis, Dimitrios T.
IMMUNOTHERAPY, 2020, 12 (07) : 481 - 510
[46] Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Spagnolo, Calogera Claudia
Giuffrida, Giuseppe
Cannavo, Salvatore
Franchina, Tindara
Silvestris, Nicola
Ruggeri, Rosaria Maddalena
Santarpia, Mariacarmela
CANCERS, 2023, 15 (01)
[47] Neurological side effects of checkpoint inhibitors
Knauss, S.
Roque, L. Ginesta
Huehnchen, P.
Heinzerling, L.
Boehmerle, W.
Endres, M.
NERVENARZT, 2019, 90 (02): : 138 - 147
[48] Pituitary and adrenal disorders induced by immune checkpoint inhibitors
Albarel, Frederique
Brue, Thierry
Castinetti, Frederic
ANNALES D ENDOCRINOLOGIE, 2023, 84 (03) : 339 - 345
[49] Type 1 diabetes induced by immune checkpoint inhibitors
Zhang, Rui
Cai, Xiao-Ling
Liu, Liu
Han, Xue-Yao
Ji, Li-Nong
CHINESE MEDICAL JOURNAL, 2020, 133 (21) : 2595 - 2598
[50] Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
Quandt, Zoe
Young, Arabella
Perdigoto, Ana Luisa
Herold, Kevan C.
Anderson, Mark S.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021, 2021, 72 : 313 - 330

← 1 2 3 4 5 →